"Durvalumab May Be Effective in Patients with EGFR+/ALK+ NSCLC."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

PD-L1 blockade with durvalumab achieves responses in patients with EGFR+/ALK+ and EGFR-/ALK- NSCLC. Click to show full abstract

PD-L1 blockade with durvalumab achieves responses in patients with EGFR+/ALK+ and EGFR-/ALK- NSCLC.

Keywords: egfr alk; durvalumab may; alk nsclc; may effective; patients egfr

Journal Title: Cancer discovery
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended